BSX

Boston Scientific is a scale medtech platform with defensible positions across interventional cardiology, electrophysiology, endoscopy, urology and neuromodulation, benefiting from procedure growth, aging demographics, and steady innovation. Recent tuck-in M&A (e.g., Valencia Technologies’ eCoin tibial nerve stimulation for urge urinary incontinence) supports adjacency expansion and reinforces its portfolio depth, though integration discipline matters. Overall, the model looks durable because demand is largely clinical-need driven and switching costs are meaningful once physician preference and hospital contracting are established.

Financially, Q1 2026 net sales were $5.203B with GAAP EPS of $0.90 and adjusted EPS of $0.80, showing strong operating leverage versus last year. Profitability appears solid (Yahoo Finance lists ~17% net margin and ~14.7% ROE) with manageable leverage (debt/equity ~42%), and the company does not pay a dividend. At ~$48/share on June 10, 2026 with TTM EPS of ~$2.39, BSX trades near ~20x trailing earnings, and management is actively returning capital via a $2B accelerated share repurchase expected to add ~$0.02 to FY2026 adjusted EPS.

The 12-month thesis is that BSX can compound earnings through mid-teens-ish sales growth plus margin expansion, while buybacks support per-share results; the next key datapoints are Q2/FY2026 execution and the July 29, 2026 earnings report. Catalysts include continued procedure recovery/volume growth, product-cycle wins in EP and structural heart, and accretive capital returns. Key risks are pricing pressure, higher-for-longer rates compressing medtech multiples, and acquisition execution (including any dilution from deal costs).

Recommendation: BUY. The combination of strong recent operating performance and an increasingly shareholder-friendly capital return program offers an attractive risk/reward at a more reasonable multiple than the prior-cycle peak.